Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ12861287-0,08
KB116711700,09
PKN100,961010,26
Msft-2,70
Nokia5,6625,6680,04
IBM-2,43
Mercedes-Benz Group AG56,4156,43-0,19
PFE1,48
19.11.2025 9:23:58
Indexy online
AD Index online
select
AD Index online
 

  • 18.11.2025
DAIICHI SANKYO (DSKYF.PK, US Other OTC (Pink Sheets))
Závěr k 18.11.2025 Změna (%) Změna (USD) Objem obchodů (ks)
21,85 0,85 0,19 11 956
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.11.2025
Popis společnosti

Business Summary: Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.
Financial Summary: BRIEF: For the six months ended 30 September 2025, Daiichi Sankyo Co Ltd revenues increased 10% to Y975.35B. Net income applicable to common stockholders decreased 11% to Y130.81B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Total selling, general and administrativ increase of 10% to Y369.43B (expense).



  • Poslední aktualizace: 19.11.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive OfficerJan Van De Winkel6301.01.2010
Chief Financial Officer, Executive Vice PresidentAnthony Pagano4701.03.2020
Executive Vice President, Chief People OfficerChristopher Cozic4701.01.2021
Executive Vice President, Chief Technical Operations OfficerRayne Waller5716.08.202416.08.2024
Executive Vice President, General Counsel, Chief Legal OfficerGreg Mueller-01.07.202501.07.2025
Executive Vice President, Chief Medical Officer, Head of Experimental MedicinesTahamtan Ahmadi5201.03.2021
Executive Vice President, Chief Commercial OfficerBrad Bailey5716.08.202416.08.2024
Executive Vice President, Chief Development OfficerJudith Klimovsky6813.02.201713.02.2017
Executive Vice President, Chief Strategy OfficerMartine Van Vugt54